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The p5 promoter region of the adeno-associated virus type 2 (AAV-2) rep gene has been described as essential
for Rep-mediated site-specific integration (RMSSI) of plasmid sequences in human chromosome 19. We report
here that insertion of a full-length or minimal p5 element between the viral inverted terminal repeats does not
significantly increase RMSSI of a recombinant AAV (rAAV) vector after infection of growth-arrested or
proliferating human cells. This result suggests that the p5 element may not improve RMSSI of rAAV vectors
in vivo.
Adeno-associated virus type 2 (AAV-2) was originally found
to be able to integrate into the AAVS1 locus of human chro-
mosome 19 in a site-specific manner (6a), and since then,
several studies have been conducted that confer this capacity to
recombinant AAV (rAAV) vectors. It was recently reported
that a 138-bp p5 region (nucleotides 151 to 289) of the AAV-2
genome is an essential cis-acting element required for Rep-
mediated site-specific integration (RMSSI) of plasmids, both
in the presence and in the absence of the viral inverted termi-
nal repeats (ITRs) (10, 11). This viral region, which includes
the promoter of the rep68/78 gene, was previously character-
ized as a cis-acting replication element (8, 9, 13), and recent
analyses defined a 55-bp p5 region (p5D10) as a minimal rep-
lication element. This region contains the TATA box, the Rep
binding site, the terminal resolution site, the Yin Yang 1
(YY1) binding site located at position 1, YY1 and a down-
stream 17-bp sequence that could potentially form a hairpin
structure (HP) with to the terminal resolution site at the top of
the loop (3). These studies also indicated that the TATA box
flanking the Rep binding site was absolutely required for in
vivo replication of the p5 element, likely through TATA bind-
ing protein-mediated enhancement of Rep-dependent binding
and nicking. Similarly, Murphy et al. recently confirmed that
mutating the TATA box severely compromised replication of
the p5 region and also found that RMSSI of p5-containing
plasmids was sensitive to the same mutations as those affecting
replication of this element (7). However, these studies, like the
previous ones, were performed by analyzing stable cell clones
derived from actively dividing cells, such as HeLa or 293 cells,
transfected with p5-containing plasmids. Therefore, the funda-
mental question that remained to be answered concerned the
effect of the p5 element on RMSSI in the context of the ITRs
and during viral infection of human cells.
Validation of the minimal 55-bp p5 element using a rAAV
plasmid-based assay. A first study was conducted to determine
if the minimal 55-bp p5 element, identified as an efficient
replication origin (3), was also able to increase RMSSI of
rAAV plasmid as previously documented for the entire p5
region. To answer this question, we used the procedure that
was previously employed by other investigators (7, 10, 11),
consisting of the analysis of stable cell clones isolated from
HeLa cells transfected with the rAAV plasmid containing dif-
ferent versions of the p5 element inserted between the ITRs
(Fig. 1). The wild-type (wt) 163-bp p5 region covers the entire
p5 promoter from the major late transcription factor binding
region to position 353, downstream from the HP region. The
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FIG. 1. Schematic view of the pAAV-GFP plasmids containing dif-
ferent versions of p5. The star indicates the presence of a mutated
TATA box, and HP indicates the position of the putative HP (3).
Positions refer to the wt AAV-2 genome (GenBank no. NC_001401).
The control pAAV-GFP plasmid contains a nonrelevant 150-bp region
instead of the p5 element.
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minimal 55-bp p5 region (p5D10) includes only the four ele-
ments previously described as essential for in vivo and in vitro
replication (Fig. 1) (3). Since our previous analysis indicated a
critical role of the TATA box for in vivo replication, two addi-
tional replication-defective p5 elements containing either a mu-
tation (p5mTATA) or a deletion (p5D12) of this binding site
were inserted into the rAAV vector plasmid. Each rAAV plas-
mid was cotransfected into HeLa cells together with a plasmid
expressing Rep under the control of doxycycline-inducible pro-
moter (pBGTetOCMVRepTS) (12). Two weeks after trans-
fection and culture in the presence of doxycycline, green flu-
orescent protein (GFP)-positive cells were sorted by a
fluorescence-activated cell sorter and cloned by limiting dilu-
tion. After expansion, each clone was analyzed for the pres-
ence of the gfp sequence by PCR and visualization of GFP
expression. As expected, only a portion of the selected clones
had integrated the gfp sequence (Table 1), and all the clones
containing this gene also expressed the protein, although at
different levels (data not shown). In each of these GFP-stable
cell clones, RMSSI was detected by Southern blot analysis
performed for EcoRI-digested DNA by using, first, an AAVS1
probe to detect rearrangements of this chromosomal region
and then, after dehybridization of the membrane, a gfp probe
to detect vector-containing bands (Fig. 2). Site-specific inte-
gration of the rAAV vector plasmid was defined by the colo-
calization of the gfp and AAVS-1 bands, as in previous studies
of RMSSI. As expected from previous studies, the presence of
the wt p5 element significantly increased site-specific integra-
tion of the rAAV plasmid compared to results with the pAAV-
GFP vector (Table 1). Insertion of the minimal p5D10 element
also had a positive effect on RMSSI, similar to that observed
for the entire p5 region. In this context, the use of long or short
replication-defective p5 elements (p5mTATA and p5D12, re-
spectively) also resulted in an increase of RMSSI, although at
a level that was apparently lower than that observed with their
respective wt counterparts. Altogether, the results of this plas-
mid-based assay indicate that the minimal 55-bp region can
increase RMSSI of the rAAV plasmid to a level similar to that
observed with the wt p5 region and that replication of this
element is not strictly required to exert this activity.
Effect of the wt and minimal p5 element during viral infec-
tion of human cells. We next asked whether an effect of the p5
element on RMSSI could similarly be observed during viral
infection of human cells. To determine this, pAAV-GFP plas-
mids containing or not containing the p5 element were used to
produce rAAV particles using a rep-expressing plasmid with
the cytomegalovirus promoter substituting for the p5 promoter
to avoid any recombination events with the p5-containing
rAAV genome. The first model used for this study was com-
posed of human hepatocyte-like cells derived after differenti-
ation of the HepaRG hepatoma cell line (1, 4). This model was
chosen because it represented human growth-arrested cells
displaying a quasi-normal karyotype, in particular concerning
chromosome 19, thus resembling conditions found during wt
and rAAV infection in vivo. For the experiments described
below, the cells were infected with rAAV-GFP particles 15
days after being cultured in conditions inducing differentiation
(4). The expression of Rep was achieved by coinfection with a
gutless adenovirus expressing the rep78 gene under the control
of a doxycycline-inducible promoter (Ad-Rep) (12). Quantita-
tive PCR was then used to analyze RMSSI of each rAAV
vector in differentiated HepaRG cells, 5 days postinfection.
FIG. 2. Representative Southern blot analysis of RMSSI in stably transfected HeLa cells clones. HeLa cells (He) were cotransfected with each
pAAV-GFP plasmid (Fig. 1) and with a second construct encoding Rep78 under the control of a doxycycline-inducible promoter (pBGTetOC
MVRepTS) (12). Whole genomic DNA extracted from of each cell clone was digested by EcoRI and analyzed by Southern blotting using an
AAVS1 probe and, after dehybridization, a gfp probe. Genomic DNA from HA-16 cells and the pAAV-GFP plasmid (GFP) served as positive
controls for AAVS1 disruption and gfp probe hybridization, respectively. The black arrow indicates the expected EcoRI restriction fragment
containing the AAVS1 sequence. The white arrows indicate AAVS1-disrupted bands that colocalize with gfp-containing bands.
TABLE 1. Analysis of HeLa cell clones transfected with AAV-GFP plasmids
Vector plasmid Total no.of clones
No. of
GFP-positive
clonesa (%)
No. of clones with AAVS1
rearrangedb/no. of GFP-
positive clones (%)
No. of clones with
RMSSIc/no. of
GFP-positive
clones (%)
pAAV-GFP 87 17 (19) 5/17 (29) 1/17 (6)
pAAVp5wt-GFP 81 32 (39) 15/32 (47) 12/32 (37)
pAAVp5mTATA-GFP 64 15 (23) 8/15 (53) 3/15 (20)
pAAVp5D10-GFP 71 19 (27) 8/19 (62) 5/19 (26)
pAAVp5D12-GFP 85 40 (48) 14/40 (35) 5/40 (12)
a As determined by PCR analysis and GFP expression.
b As determined by Southern blotting using an AAVS1 probe.
c Number of clones with AAV sequences integrated in AAVS1 region as determined by Southern blot analysis using gfp and AAVS1 probes.
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This assay, previously described by Hu¨ser et al. (5, 6), allowed
the detection of rAAV vector integration in both orientations
(Fig. 3A). By use of this protocol, detectable levels of RMSSI
integration were measured in cells coinfected with AAV-GFP
vectors and Ad-Rep in the presence of doxycycline but not in
the absence of Rep (Fig. 3B). Surprisingly, however, the use of
the AAVp5D10-GFP vector did not significantly increase
RMSSI compared with results for the AAV-GFP virus (mean
FIG. 3. Quantification of RMSSI in transduced HepaRG cells. (A) Human chromosome 19 region (GenBank accession no. AC010327) and
position of primers pAAVS1 (5-TCAGAGGACATCACGTG-3) and pITR (5-TTAACTACAAGGAACCCCTA-3) used for the amplification
of AAVS1-AAV junctions by quantitative PCR. D and A indicate the positions of the donor (5-TGTTGCTGCCCAAGGATGCT-FL; TIB
Molbiol) and acceptor (5-LC Red640-TTTCCGGAGCACTTCCTTCTCG-p; TIB Molbiol) probes, respectively. The number of integrated AAV
copies in the AAVS1 locus was measured by using as a standard different copies of the pAAVS1-ITR control plasmid that carries an artificial
AAVS1-chromosome 19 junction fragment (5, 6) and was further calibrated by using genomic DNA extracted from HA-16 cells that contain the
wt AAV-2 genome integrated into the AAVS1 site in a head-to-tail configuration (2). Results are expressed as the percentage of AAVS1-ITR
junctions found in each sample relative to the number of junctions found using equivalent amounts of HA-16 cells. (B) Differentiated HepaRG
cells were transduced with AAV-GFP or AAVp5D10-GFP in the presence or in the absence of a gutless adenovirus encoding Rep78 under the
control of a doxycycline-inducible promoter (12). Alternatively, the cells were infected with wt AAV-2 particles (multiplicity of infection, 4,000
physical particles/cell and 20 infectious particles/cell for rAAV and adenoviral vectors, respectively). The percentage of RMSSI was measured for
HepaRG cells 5 days after transduction. CTRL, genomic DNA from nontransduced HepaRG cells. (C) HeLa cells were transfected with the
Rep-expressing plasmid (pBGTetOCMVRepTS) and then infected with rAAV. Alternatively, the cells were infected with wt AAV2 particles. Both
infections were performed at a multiplicity of infection of 4,000 particles/cell. RMSSI was measured by quantitative PCR 3 days after infection and
culture in the presence of doxycycline.
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integration frequencies of 3.4  2.5% and 4.0  3.1%, respec-
tively). To examine whether higher levels of site-specific inte-
gration could be achieved using a viral genome with a p5
element and the rep gene on the same DNA molecule, we
measured RMSSI after infection of differentiated HepaRG
cells with wt AAV-2 particles. The integration frequency using
wt AAV2 particles was approximately 0.5  0.3%, thus indi-
cating that RMSSI in this cell type could not be enhanced even
using this optimal substrate (Fig. 3B). Altogether, these results
indicated that insertion of the minimal p5 element did not
enhance RMSSI of a rAAV vector during infection of growth-
arrested cells.
To determine whether this result could be attributed to the
cell type chosen for this assay, a similar experiment was con-
ducted using HeLa cells that were transfected with the doxy-
cycline-inducible Rep plasmid (pBGTetOCMVRepTS) and
then infected with AAV-GFP particles containing either the
full-length or the minimal p5 element. RMSSI was measured
by quantitative PCR for the cell population 3 days after infec-
tion in the presence of doxycycline. By using this protocol, a
higher level of RMSSI was detected when HeLa cells were
infected with wt AAV2 particles than with HepaRG cells (Fig.
3C). When cells were infected with rAAV vectors, detectable
levels of RMSSI events were measured only in cells infected in
the presence of Rep. However, as previously observed for
HepaRG cells, the insertion of the wt or minimal p5 element
in the rAAV vector did not significantly increase RMSSI com-
pared with results for the AAV-GFP virus (mean integration
frequencies of 23.3  13.5%, 29.5  13.2%, and 33.9  18.0%
for AAV-GFP, AAVp5wt-GFP, and AAVp5D10-GFP, respec-
tively).
Altogether, this study documents for the first time the effect
of the p5 element in the context of a viral infection. We show
that insertion of the p5 region, in either its wt or its minimal
version, cannot significantly increase RMSSI of a rAAV vector
during infection of proliferating or quiescent human pseudo-
primary cells. This result contrasts with the effect previously
observed in this and other studies analyzing RMSSI of p5-
containing rAAV plasmids after transfection into individual
cell clones. This differential effect may depend upon the rAAV
substrate introduced into the cells (i.e., a plasmid versus a
linear molecule) or the selection procedure performed to ob-
tain individual cell clones. Further studies should be conducted
to determine whether, likewise, insertion of the p5 element is
dispensable for enhancing RMSSI of rAAV vectors in vivo.
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